Table 6.
Treatment and outcomes in 32 patients included in stage IV of the disease.
| Treatment | Total no. of patients/% | Total remission no. of patients/% | Partial remission no. of patients/% | Death of disease no. of patients/% |
|---|---|---|---|---|
| Surgery | ||||
| TAH | 5/15.6% | 1/20.0% | – | 4/80.0% |
| TAH/BSO | 7/21.9% | – | 2/ 28.6% | 5/71.4% |
| NOS | 6/18.8% | 0/0.0% | 1/16.7% | 5/83.3% |
| MTS | 3/9.4% | – | 2/66.7% | 1/33.3% |
| TAH/BSO/MTS | 9/28.1% | 3/ 33.3% | 3/33.3% | 3/33.3% |
| TE/MTS | 1/1/3.1% | – | 1/100% | – |
| SPS | 1/3.1% | – | – | 1/ 100% |
| Total | 32 | 4/ 12.5% | 9/ 28.1% | 19/ 59.4% |
| First-line chemotherapy | ||||
| EMA/CO | 13/40.6% | 1/7/7% | 3/23.1% | 9/69.2% |
| FAEV | 8/25.0% | – | 1/12.5% | 7/87.5% |
| EMA/EP | 5/15.6% | 1/20.0% | 4/80.0% | – |
| EP/EMA | 3/ 9.4% | 1/33.3% | 1/33.3% | 1/33.3% |
| NO-CHEMO | 1/3.4% | 1/100% | – | – |
| BEP | 1/3.1% | - | – | 1/100% |
| CEC | 1/3.1% | 1/100% | ||
| Second-line chemotherapy | ||||
| NO-CHEMO | 19/ 59.4% | 4/21.0% | 4/21.0% | 11/57.9% |
| EMA/CO | 6/18.8% | 1/16.7% | 5/83.3% | |
| TIP | 1/3.1% | – | – | 1/100% |
| Pembrolizumab | 2/ 6.3% | – | 2/100% | – |
| BEP | 1/3.1% | 1/100% | ||
| VIP | 1/3.1% | 1/100% | ||
| C/T | 2/6.3% | – | 2/100% |